Skip to Content
Søg Menu

ECCO 2019: Vedolizumab and anti-TNF in Crohn’s disease are equally effective

In this MEDtalk Brian Bressler present data from a multi-country, retrospective chart review study assessed the effectiveness and safety of vedolizumab compared with anti-tumour necrosis factors  agents in a real-world cohort of biologic-naïve Crohn’s disease patients.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Karina Winther Andersen

Patients’ Gender Roles and Coping Strategies are Important Topics in Health Care Professionals Dialogue with Crohn’s Patients

/ Karina Winther Andersen
CrohnIBDSeksuel sundhed Play the Video 5:53

Blodprøver viser tegn på inflammatoriske tarmsygdomme op til 8 år før diagnose

/ Marie Vibeke Vestergaard / Tine Jess / Kristine Højgaard Allin
Colitis ulcerosaCrohnIBD
Marc Ferrante

Mirikizumab As a Potential New Treatment in Patients with Crohn’s Disease

/ Marc Ferrante
CrohnECCO24 Play the Video 8:36
Daniele Noviello

Risankizumab Downregulates IL-23-Induced Mucosal Pathogenic Th17 Cells in Patients with Crohn’s Disease

/ Daniele Noviello
CrohnECCO24 Play the Video 5:49
Anja Poulsen

Colon Involvement or Isolated Small Intestinal Resection is Associated with a Higher Risk of Re-Resection in Crohn’s Disease Patients

/ Anja Poulsen
CrohnECCO24 Play the Video 04:49
Joana Revés

No Association Between Bowel Damage and Disability in Patients with Recently Diagnosed Crohn’s Disease

/ Joana Revés
CrohnECCO24 Play the Video 06:52

Så både patient og sygeplejerske får det hele med – fra kvalitetsindikator til den kliniske hverdag

/ Else Kjær Mikkelsen
Colitis ulcerosaCrohnIBD

AI-Assisted Pan-Enteric Capsule Endoscopy: A Fast Look at Suspected Crohn’s

/ Jacob Broder Brodersen
CrohnIBD

Three-Fold Increased Risk of Anorectal Cancer in Crohn’s Disease Patients with Fistulas

/ Alaa El-Hussuna
CrohnCancer
Back to top